Jenny C. Chang

24.0k total citations · 4 hit papers
219 papers, 14.0k citations indexed

About

Jenny C. Chang is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jenny C. Chang has authored 219 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 77 papers in Molecular Biology and 69 papers in Cancer Research. Recurrent topics in Jenny C. Chang's work include Breast Cancer Treatment Studies (30 papers), Cancer Cells and Metastasis (27 papers) and HER2/EGFR in Cancer Research (25 papers). Jenny C. Chang is often cited by papers focused on Breast Cancer Treatment Studies (30 papers), Cancer Cells and Metastasis (27 papers) and HER2/EGFR in Cancer Research (25 papers). Jenny C. Chang collaborates with scholars based in United States, Germany and United Kingdom. Jenny C. Chang's co-authors include Susan G. Hilsenbeck, Gary C. Chamness, C. Kent Osborne, Jeffrey M. Rosen, Anna Tsimelzon, Richard Elledge, Bhuvanesh Dave, Michael T. Lewis, Carolina Gutiérrez and D. Craig Allred and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Jenny C. Chang

210 papers receiving 13.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

2008 1.4k citations Michael T. Lewis, Carolina Gutiérrez et al. profile →
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

2014 936 citations Matthew D. Burstein, Anna Tsimelzon et al. Clinical Cancer Research profile →
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

2003 668 citations Jenny C. Chang, Anna Tsimelzon et al. profile →
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1998 649 citations Jenny C. Chang et al. profile →

Peers

Jenny C. Chang

ONCOL

GENET

PRM

Douglas Yee United States

Jalid Sehouli Germany

Sofía D. Merajver United States

Robert L. Coleman United States

Nicole Urban United States

Heidi L. Weiss United States

Michael S. Pepper South Africa

Emile E. Voest Netherlands

Peggy L. Porter United States

Michael J. Kerin Ireland

Douglas Yee United States

Jenny C. Chang

6.1k ×0.9

ONCOL

9.9k ×1.7

4.1k ×0.9

2.1k ×1.2

GENET

1.8k ×1.1

PRM

Citations per year, relative to Jenny C. Chang Jenny C. Chang (= 1×) peers Douglas Yee

Countries citing papers authored by Jenny C. Chang

Since Specialization

Citations

This map shows the geographic impact of Jenny C. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny C. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny C. Chang more than expected).

Fields of papers citing papers by Jenny C. Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny C. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny C. Chang. The network helps show where Jenny C. Chang may publish in the future.

Co-authorship network of co-authors of Jenny C. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny C. Chang. A scholar is included among the top collaborators of Jenny C. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny C. Chang. Jenny C. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Jenny C., et al.. (2024). The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer. Frontiers in Physiology. 15. 1358850–1358850. 4 indexed citations

Jain, Dharamvir, et al.. (2024). Abstract PO5-12-09: A Single-Arm Pilot Study of the Feasibility and Efficacy of Electro-Acupuncture in Subjects with Chemotherapy-Induced Peripheral Neuropathy. Cancer Research. 84(9_Supplement). PO5–12.

Zinger, Assaf, Manuela Sushnitha, Tomoyuki Naoi, et al.. (2021). Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles. ACS Nano. 15(4). 6326–6339. 67 indexed citations

Chang, Jenny C., et al.. (2020). Arp2/3 nucleates F-actin coating of fusing insulin granules in pancreatic β cells to control insulin secretion. Journal of Cell Science. 133(6). 15 indexed citations

Boakye, Daniel, Viola Walter, Min Young Um, et al.. (2019). Treatment selection bias for chemotherapy persists in colorectal cancer patient cohort studies even in comprehensive propensity score analyses. SHILAP Revista de lepidopterología. 2 indexed citations

Dávila‐González, Daniel, Dong Soon Choi, Roberto R. Rosato, et al.. (2018). Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clinical Cancer Research. 24(5). 1152–1162. 68 indexed citations

Hollander, Petra den, Anna Tsimelzon, Jonathan H. Shepherd, et al.. (2016). Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research. 76(7). 1942–1953. 70 indexed citations

Burstein, Matthew D., Anna Tsimelzon, Graham M. Poage, et al.. (2014). Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research. 21(7). 1688–1698. 936 indexed citations breakdown →

Yu, Ke‐Da, Rui Zhu, Ming Zhan, et al.. (2013). Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer. Clinical Cancer Research. 19(10). 2723–2733. 127 indexed citations

10.

Schott, Anne F., Melissa D. Landis, Gabriela Dontu, et al.. (2013). Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research. 19(6). 1512–1524. 209 indexed citations

11.

Zhao, Hong, Guangxu Jin, Kemi Cui, et al.. (2013). Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases. Cancer Research. 73(20). 6149–6163. 28 indexed citations

12.

Crew, Katherine D., Powel H. Brown, Heather Greenlee, et al.. (2012). Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer. Cancer Prevention Research. 5(9). 1144–1154. 76 indexed citations

13.

Chakrabarty, Anindita, Neil E. Bhola, Cammie R. Sutton, et al.. (2012). Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors. Cancer Research. 73(3). 1190–1200. 101 indexed citations

14.

Jin, Guangxu, et al.. (2011). A Novel Method of Transcriptional Response Analysis to Facilitate Drug Repositioning for Cancer Therapy. Cancer Research. 72(1). 33–44. 61 indexed citations

15.

Garrett, Joan T., Maria G. Olivares, Cammie Rinehart, et al.. (2011). Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences. 108(12). 5021–5026. 359 indexed citations

16.

Litzenburger, Beate C., Chad J. Creighton, Anna Tsimelzon, et al.. (2010). High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy. Clinical Cancer Research. 17(8). 2314–2327. 109 indexed citations

17.

Speers, Corey, Anna Tsimelzon, K. Sexton, et al.. (2009). Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer. Clinical Cancer Research. 15(20). 6327–6340. 77 indexed citations

18.

Key, Timothy J., Gary E. Fraser, Margaret Thorogood, et al.. (1998). Mortality in vegetarians and non-vegetarians: a collaborative analysis of 8300 deaths among 76,000 men and women in five prospective studies. Public Health Nutrition. 1(1). 33–41. 120 indexed citations

19.

Yoshiura, Koh-ichiro, et al.. (1997). Genomic structure, sequence, and mapping of humanFGF8 with no evidence for its role in craniosynostosis/limb defect syndromes. American Journal of Medical Genetics. 72(3). 354–362. 17 indexed citations

20.

Chang, Jenny C., J Wahrendorf, Nina M. Muñoz, et al.. (1990). An epidemiological study of precursor lesions of esophageal cancer among young persons in a high-risk population in Huixian, China.. PubMed. 50(8). 2268–74. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact